logo

For the Inventor, By the Inventor

Södertälje, Sweden

Tobias Rein

This inventor holds 5 USPTO granted patents and 2 published patent applications and 2 EPO patents. Top assignees: Astrazeneca Ab, Acturum Life Science Ab. Active years: 2011-2016.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Tobias Rein. Retrieved from https://idiyas.com/inventor/tobias-rein

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 5 

% Patents Active = 60.0


Average Co-Inventor Count = 4.6

ph-index = 2

Forward Citations = 6(Granted Patents)


Location History:

  • Sodertalje, SE (2011 - 2012)
  • Södertälje, SE (2011 - 2016)

Company Filing History:

goldMedal4 out of 1,534 
 
Astrazeneca Ab
 patents
silverMedal1 out of 6 
 
Acturum Life Science Ab
 patents

Years Active: 2011-2016

Loading Chart...
Loading Chart...
5 patents (USPTO):Explore Patents
1. 9440992 - 5,7-disubstituted thiazolo[4,5-D]pyrimidines as chemokine inhibitors (2016-09-13),
2. 8158785 - 5,7-disubstituted[1.3]thiazolo [4,5-D] pyrimidin-2(3H)-amine derivatives and their use in therapy (2012-04-17),
3. 8088780 - 5,7-disubstituted thiazolo[4,5-D]pyrimidines for the selective inhibition of chemokine receptors (2012-01-03),
4. 7960395 - 5,7-disubstituted thiazolo[4,5-d]pyrimidines for the selective inhibition of chemokine receptors (2011-06-14),
5. 7947693 - 5,7-disubstituted thiazolo[4,5-D]pyrimidines as chemokine inhibitors (2011-05-24),

Title: The Innovative Contributions of Tobias Rein

Introduction

Tobias Rein is a notable inventor based in Södertälje, Sweden. He has made significant contributions to the field of pharmaceuticals, particularly in the development of novel compounds for therapeutic use. With a total of 5 patents to his name, Rein's work focuses on addressing various medical conditions through innovative chemical solutions.

Latest Patents

Rein's latest patents include the development of 5,7-disubstituted thiazolo[4,5-D]pyrimidines as chemokine inhibitors. These novel compounds are designed as CXCR1 receptor antagonists, which are particularly useful in the treatment or prophylaxis of neurodegenerative disorders, demyelinating diseases, and various cardiovascular conditions. His work also encompasses 5,7-disubstituted [1.3]thiazolo [4,5-D]pyrimidin-2(3H)-amine derivatives, which share similar therapeutic applications.

Career Highlights

Throughout his career, Tobias Rein has worked with prominent companies such as AstraZeneca AB and Acturum Life Science AB. His experience in these organizations has allowed him to refine his expertise in pharmaceutical innovation and contribute to significant advancements in drug development.

Collaborations

Rein has collaborated with notable colleagues, including Gunnar Nordvall and Colin Ray. These partnerships have facilitated the exchange of ideas and expertise, further enhancing the impact of his work in the pharmaceutical industry.

Conclusion

Tobias Rein's innovative contributions to the field of pharmaceuticals demonstrate his commitment to improving healthcare through scientific advancements. His patents reflect a deep understanding of complex medical challenges and a dedication to finding effective solutions.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…